Coexistence of anti-KS and anti-TIF1-γ antibodies in clinically amyopathic dermatomyositis presenting with rapid progression of interstitial lung disease.
Yuichiro OtaToshiki OhisaAkira IshiiMai SugiyamaYasushi KondoAyumi NishikawaNoriko SasakiChiho YamadaShinji SatoPublished in: Modern rheumatology case reports (2024)
Polymyositis/Dermatomyositis (PM/DM) is an idiopathic inflammatory myopathy (IIM) manifesting mainly as symmetrical proximal muscle weakness and/or typical cutaneous features due to autoimmune mechanisms. Clinically amyopathic dermatomyositis (CADM) is a subset of DM that exhibits only the typical cutaneous features without any clinical muscle symptoms. Several autoantibodies have been found specifically in patients with PM/DM, including CADM patients. Anti-KS antibody is one of a group of anti-aminoacyl transfer RNA (ARS) antibodies that are mainly associated with fever, Raynaud's phenomenon, polyarthritis, and interstitial lung disease (ILD), whereas anti-TIF1-γ antibody is frequently found in DM patients with malignancy. Here, we report a CADM patient having both anti-KS antibody and anti-TIF1-γ antibody. This patient developed an acute exacerbation of ILD and was successfully treated with high dose corticosteroid pulse therapy together with immunosuppressive agents. Although earlier experience had indicated that the seminal characteristic of anti-KS-positive ILD was slowly developing disease onset with little or no progression over the clinical course, the present patient suffered rapidly progressive disease.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- high dose
- case report
- end stage renal disease
- chronic obstructive pulmonary disease
- newly diagnosed
- chronic kidney disease
- air pollution
- skeletal muscle
- blood pressure
- low dose
- mesenchymal stem cells
- disease activity
- stem cells
- hepatitis b virus
- prognostic factors
- ejection fraction
- depressive symptoms
- insulin resistance
- adipose tissue
- peritoneal dialysis
- aortic dissection
- patient reported outcomes
- water soluble
- cell therapy